Hengrui Pharma / 恒瑞医药

Hengrui Pharma / 恒瑞医药 appears in vol.117.生物医药的2025：抄底中国、研发焦虑和新王继位 as a Chinese pharma company linked to [[BiotechLicenseOutArbitrage|license-out]] and [[ReverseNewCoBiotechModel|reverse NewCo]] examples. The episode says one Hengrui pipeline was licensed for a relatively small upfront payment and later transferred at a much higher implied value, illustrating the China-U.S. asset-pricing gap.

Hengrui’s role in the source is structural rather than a full company profile. It is used to show why Chinese companies may try new transaction forms when ordinary license-out leaves too much upside with offshore intermediaries.

Connections

• Biotech License-Out Arbitrage - source example of value leakage through asset repricing.
• Reverse NewCo Biotech Model - newer transaction form associated with Chinese pipelines moving overseas.
• China Biotech Asset Repricing - broader market-pricing frame.